Clinical Trials Browser

INDUSTRY × navitoclax × Myeloid × Clear all

NCT04472598 2026-03-23

TRANSFORM-1

Phase 3 Completed

252 enrolled 17 charts

Neoplasms, Primary Myelofibrosis

NCT04468984 2026-01-09

TRANSFORM-2

Phase 3 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04454658 2025-07-16

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Active not recruiting

Neoplasms, Primary Myelofibrosis

NCT04041050 2025-02-14

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Neoplasms, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT03592576 2024-05-06

Expanded Access to Navitoclax

No longer available

LymphoidMyeloidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

Phase 1 Terminated

Neoplasms, Primary Myelofibrosis